160 related articles for article (PubMed ID: 27149478)
21. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer.
Tachibana M; Takemoto Y; Nakashima Y; Kinugasa S; Kotoh T; Dhar DK; Kohno H; Nagasue N
J Am Coll Surg; 1998 Jul; 187(1):64-8. PubMed ID: 9660027
[TBL] [Abstract][Full Text] [Related]
22. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
23. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
[TBL] [Abstract][Full Text] [Related]
24. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
25. Gastric neuroendocrine neoplasms.
Lamberti G; Panzuto F; Pavel M; O'Toole D; Ambrosini V; Falconi M; Garcia-Carbonero R; Riechelmann RP; Rindi G; Campana D
Nat Rev Dis Primers; 2024 Apr; 10(1):25. PubMed ID: 38605021
[TBL] [Abstract][Full Text] [Related]
26. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
27. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract][Full Text] [Related]
28. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of early postoperative tumor marker response in gastric cancer.
Nam DH; Lee YK; Park JC; Lee H; Shin SK; Lee SK; Lee YC; Cheong JH; Hyung WJ; Noh SH; Kim CB
Ann Surg Oncol; 2013 Nov; 20(12):3905-11. PubMed ID: 23807661
[TBL] [Abstract][Full Text] [Related]
30. [Surgical treatment and prognosis of Borrmann type IIII( gastric cancer involving the whole stomach].
Dong R; Zhang Z; Zhou Y; Hua Y; Guo J
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Feb; 21(2):185-189. PubMed ID: 29492918
[TBL] [Abstract][Full Text] [Related]
31. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.
Yu X; Hu F; Yao Q; Li C; Zhang H; Xue Y
BMC Cancer; 2016 Jul; 16():480. PubMed ID: 27418164
[TBL] [Abstract][Full Text] [Related]
32. Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection.
Liu X; Qiu H; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z; Sun X
Oncotarget; 2016 Jun; 7(23):35446-53. PubMed ID: 27147574
[TBL] [Abstract][Full Text] [Related]
33. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
[No Abstract] [Full Text] [Related]
34. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
35. Defining prognostic parameters of well-differentiated gastric neuroendocrine tumors based on metastatic potential: a two-center experience.
Kurtulan O; Turhan N; Gedikoğlu G; Akyol A; Sökmensüer C
Acta Gastroenterol Belg; 2022; 85(2):339-345. PubMed ID: 35709778
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
37. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.
Cai D; Huang ZH; Yu HC; Wang XL; Bai LL; Tang GN; Peng SY; Li YJ; Huang MJ; Cao GW; Wang JP; Luo YX
World J Gastroenterol; 2019 Sep; 25(33):4945-4958. PubMed ID: 31543685
[TBL] [Abstract][Full Text] [Related]
39. Surgical indication of type I gastric neuroendocrine tumors.
Ruiz Pardo J; Sánchez Fuentes PA; Vidaña Márquez E; García-Redondo M; González Sánchez D; Belda Lozano R; Ferrer-Márquez M; Reina Duarte Á
Rev Esp Enferm Dig; 2024 May; 116(5):280-282. PubMed ID: 37170558
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well-differentiated gastric cancer. A multivariate analysis.
Maehara Y; Kusumoto T; Takahashi I; Kakeji Y; Baba H; Akazawa K; Sugimachi K
Oncology; 1994; 51(3):234-7. PubMed ID: 8196905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
